Boston Scientific (BSX) AI Stock Analysis

• Market Cap: $146.97B
• Dividend Yield: N/A
• Average Volume (3M): 6.79M
• Price to Earnings (P/E): 72.8
• Beta (1Y): 0.83
• Revenue Growth: 19.35%
• EPS Growth: 14.31%
• Country: US
• Employees: 53,000
• Sector: Healthcare
• Sector Strength: 55
• Industry: Medical - Devices
• EPS (TTM): 0.75
• Shares Outstanding: 1,479,446,300
• 10 Day Avg. Volume: 7,985,531
• 30 Day Avg. Volume: 6,792,575
• PEG Ratio: -2.73
• Price to Book (P/B): 3.77
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 72.42
• Enterprise Value/Market Cap: 0.51
• Enterprise Value/Revenue: 1.14
• Enterprise Value/Gross Profit: 6.32
• Enterprise Value/Ebitda: 4.86
• 1Y Price Target: $120.40
• Price Target Upside: 22.16% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 22

• Rating: 71 Outperform
• Price Target: $110.00 ▲(11.61%Upside)

Boston Scientific demonstrates strong financial performance and positive earnings call results. However, high valuation levels and technical indicators suggest caution in the short term. The decision to cease certain product lines and the potential financial impact of tariffs could present risks, but strategic initiatives in high-growth areas like cardiology and electrophysiology offer promising long-term prospects.

Positive Factors

Growth Drivers

BSX expects to offset the impact of the ACURATE discontinuation with its other growth drivers including continued strong growth from FARAPULSE and WATCHMAN.

Market Position

BSX has seen its EP share increase to #2 in certain markets and is executing to become clear leader in the electrophysiology space.

Revenue Opportunities

BSX expects to disrupt how mapping is done with the recent launch of Faraview and Farawave Nav, which can be an incremental $2k-$4k revenue opportunity per case.

Negative Factors

Product Discontinuation

Boston Scientific announced the discontinuation of global Acurate neo2 and Acurate Prime TAVR valve sales, announcing that it would no longer be pursuing approval in the U.S. or other regions.

Regulatory Challenges

The decision was driven by recent discussions with US and European regulators, and management felt that the increased clinical evidence and regulatory hurdles needed to maintain product approvals globally for ACURATE would not be worth the investment.

Boston Scientific Business Overview & Revenue Model

Company Description

Boston Scientific Corporation (BSX) is a leading global medical technology company that develops, manufactures, and markets a wide range of medical devices used in various interventional medical specialties. The company operates in three main sectors: Cardiovascular, Rhythm Management, and MedSurg. Its core products include stents, catheters, pacemakers, implantable cardioverter-defibrillators, and other devices used in interventional cardiology, electrophysiology, endoscopy, urology, and pelvic health.

How the Company Makes Money

Boston Scientific makes money primarily through the sale of its medical devices and technologies across its different business sectors. The company generates revenue from hospitals, clinics, and health systems that purchase its products for use in various medical procedures. Key revenue streams for Boston Scientific include its Cardiovascular segment, which offers products for coronary interventions, structural heart therapies, and peripheral interventions; the Rhythm Management segment, providing devices for cardiac rhythm disorders; and the MedSurg segment, which includes products for endoscopy, urology, and pelvic health. Additionally, Boston Scientific benefits from strategic partnerships and acquisitions that enhance its product portfolio and expand its market presence, contributing to its overall earnings.

Boston Scientific Financial Statement Overview

Summary

Boston Scientific shows strong financial performance with consistent revenue growth, solid profitability, and efficient cash flow management. The company maintains a healthy balance sheet with manageable leverage and strong equity returns. However, there is room for improvement in further reducing debt levels.

Income Statement

Boston Scientific has demonstrated robust growth in its revenue, with a notable TTM (Trailing-Twelve-Months) increase of 4.81% compared to the previous year. The company maintains strong gross and net profit margins at 67.15% and 11.57% respectively, indicating efficient cost management and profitability. The EBIT and EBITDA margins are solid at 17.52% and 21.65%, reflecting operational efficiency. Overall, the company shows a positive growth trajectory in the medical devices industry.

Balance Sheet

The balance sheet reflects a healthy financial position with a Debt-to-Equity ratio of 0.51, showing manageable leverage. The Return on Equity (ROE) stands at a strong 9.15%, indicating effective utilization of shareholders' equity. The Equity Ratio is 55.33%, suggesting a stable asset base supported by equity. Overall, the company maintains a strong balance between debt and equity, although there is room for improvement in reducing debt levels.

Cash Flow

Boston Scientific exhibits strong cash flow management with a Free Cash Flow growth rate of 8.62%, indicating improved cash generation. The Operating Cash Flow to Net Income ratio is 1.88, demonstrating the company's ability to convert income into cash efficiently. The Free Cash Flow to Net Income ratio is 1.41, reflecting good cash flow productivity. Overall, the company shows robust cash flow health, supporting its financial stability and operational needs.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
17.55B	16.75B	14.24B	12.68B	11.89B	9.91B
	Gross Profit
11.79B	11.49B	9.89B	8.68B	8.13B	6.40B
	EBIT
3.08B	2.60B	2.34B	1.65B	2.04B	1.04B
	EBITDA
4.09B	3.94B	3.45B	2.74B	2.52B	1.51B
	Net Income Common Stockholders
2.03B	1.85B	1.59B	698.00M	1.04B	-140.00M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
725.00M	414.00M	865.00M	928.00M	1.93B	1.73B
	Total Assets
40.14B	39.40B	35.14B	32.47B	32.23B	30.78B
	Total Debt
11.71B	11.15B	9.49B	9.28B	9.45B	9.54B
	Net Debt
10.98B	10.73B	8.63B	8.35B	7.53B	7.80B
	Total Liabilities
17.69B	17.39B	15.61B	14.90B	15.61B	15.45B
	Stockholders Equity
22.21B	21.77B	19.28B	17.57B	16.62B	15.33B
Cash Flow		Free Cash Flow
2.87B	2.65B	1.70B	914.00M	1.32B	1.13B
	Operating Cash Flow
3.81B	3.44B	2.50B	1.53B	1.87B	1.51B
	Investing Cash Flow
-5.90B	-5.69B	-2.57B	-2.01B	-1.60B	-411.00M
	Financing Cash Flow
2.15B	1.81B	5.00M	-548.00M	-95.00M	293.00M

Boston Scientific Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 98.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BSX, the sentiment is Negative. The current price of 98.56 is below the 20-day moving average (MA) of 103.51, below the 50-day MA of 100.74, and above the 200-day MA of 94.37, indicating a neutral trend. The MACD of -0.73 indicates Positive momentum. The RSI at 33.83 is Neutral, neither overbought nor oversold. The STOCH value of 6.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BSX.

Boston Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DXCM	81 Outperform	$32.54B	62.20	23.72%	―	9.11%	-17.87%
ABT	80 Outperform	$233.36B	17.40	30.66%	1.74%	5.00%	139.98%
SYK	78 Outperform	$147.15B	51.96	14.26%	0.88%	10.76%	-15.22%
MDT	75 Outperform	$112.81B	24.37	9.49%	3.18%	3.62%	31.18%
BSX	71 Outperform	$146.97B	72.83	9.65%	―	19.35%	14.31%
EW	71 Outperform	$44.27B	50.70	16.73%	―	-9.84%	-35.77%
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%

Boston Scientific Corporate Events

Boston Scientific Discontinues Aortic Valve Systems

On May 28, 2025, Boston Scientific announced the discontinuation of its ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems, ceasing global sales and halting pursuit of FDA approval due to increased regulatory demands. Despite the financial implications, the company expects to meet its sales and earnings guidance for 2025, though it is withholding reaffirmation of its GAAP EPS guidance until further updates in its second quarter earnings call.

The most recent analyst rating on (BSX) stock is a Buy with a $113.00 price target. To see the full list of analyst forecasts on Boston Scientific stock, see the BSX Stock Forecast page.

Boston Scientific Stockholders Approve Key Governance Proposals

On May 1, 2025, Boston Scientific held its Annual Meeting of Stockholders virtually, where all 10 director nominees were elected for a one-year term. Additionally, stockholders approved the compensation for the company’s Named Executive Officers, ratified the appointment of Ernst & Young LLP as the independent public accounting firm for 2025, and supported a proposal for a simple majority vote, indicating strong shareholder engagement and support for the company’s governance and strategic direction.

Boston Scientific Announces CFO Retirement and Successor

On April 23, 2025, Boston Scientific announced the retirement of Dan Brennan, its Chief Financial Officer, after nearly 30 years with the company. Brennan will be succeeded by Jon Monson, currently the Senior Vice President of Investor Relations, effective June 30, 2025. Monson, with over 25 years at Boston Scientific, brings extensive financial expertise and will oversee several key company functions. This leadership transition is expected to ensure continuity and further strengthen the company’s financial strategies and operations.